6533b836fe1ef96bd12a11fb

RESEARCH PRODUCT

Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.

Marc PeetersRiccardo AlessandroJan P. Van MeerbeeckChristian RolfoJorge Jorge ChacarteguiPablo ReclusaMarco GiallombardoPatrick Pauwels

subject

0301 basic medicineCancer Researchbusiness.industrynon-small cell lung cancer (NSCLC)medicine.diseaserespiratory tract diseases03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyEgfr mutation030220 oncology & carcinogenesismedicineCancer researchExosomal mirnasPrognostic biomarkerOsimertinibbusinessneoplasmsTyrosine kinase

description

e23035Background: NSCLC patients harboring EGFR mutations are able to receive approved tyrosine kinase inhibitors (TKIs) but to better assess the treatment responses new tools are needed. Liquid bi...

https://doi.org/10.1200/jco.2016.34.15_suppl.e23035